Clinical trials: Gene Mutations
NSCLC
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
This is a multicenter, randomized controlled, double-blind clinical trial. The study is designed to evaluate the efficacy and safety of high-dose Almonertinib versus Osimertinib in the second-line treatment of patients with EGFR…
- Trial name
- ATTACK (NCT04870190)
- Testing
- Almonertinib, Osimertinib
- Volunteers
- 232 people
- Sponsor
- Shanghai Chest Hospital
Advanced Non Small Cell Lung Cancer (NSCLC)
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.
- Trial name
- NCT01646125
- Testing
- AUY922, Docetaxel, Pemetrexed
- Where
- 27 sites in United States, France and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Citrate Transporter Deficiency, SLC13A5 Gene Mutation
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency
The purpose of this study is to determine whether triheptanoin (UX007) is effective in the treatment of neurological symptoms related to citrate transporter deficiency (SLC13A5 gene mutation).
- Trial name
- NCT02500082
- Testing
- triheptanoin
- Where
- United States
- Sponsor
- Irina A Anselm
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine)…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT06998940
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- 274 sites in United States
- Volunteers
- 94 people
- Sponsor
- SWOG Cancer Research Network
Mediastinal Lymphadenopathy, Hilar Lymphadenopathy
Endobronchial Ultrasound Needle Aspiration With and Without Suction
The main purpose of the present study is to compare the diagnostic yield of different aspiration techniques in Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) in the diagnosis of hilar/mediastinal adenopathy
- Conditions
- Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lung Neoplasms
- Trial name
- NCT05110950
- Testing
- No suction EBUS-TBNA, Passive suction through dedicated EBUS-TBNA syringe, Manual applied suction EBUS-TBNA through a pistol-grip syringe holder
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Università Politecnica delle Marche
Neoplasms, Therapy-Associated
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene…
- Trial name
- NCT02283424
- Testing
- Icotinib, chemotherapy (Carboplatin and Docetaxel)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Pancreas Cancer
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients.
- Trial name
- NCT00300950
- Testing
- GI-4000, Gemcitabine
- Where
- 28 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- GlobeImmune
Recurrent/Advanced Gastric Cancer
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Clinical Indication : HER mutated or HER2 Amplification/Overexpression in Gastric Cancer, 2nd-line Trial Type : Interventional, Open label Treatment Groups : Single arm: Pembrolizumab 200 mg every 3 weeks (Q3W), neratinib at 240…
- Trial name
- NCT05512182
- Testing
- Chemotherapy
- Where
- South Korea
- Sponsor
- Yonsei University
Retinitis Pigmentosa
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis Pigmentosa.
- Trial name
- NCT06291935
- Testing
- VG901
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- VeonGen Therapeutics GmbH
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
- Conditions
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
- Trial name
- NCT04965818
- Testing
- Futibatinib and Binimetinib
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Taiho Oncology, Inc.
Acute Myeloid Leukemia
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
Erwinaze will be administered intravenously at a dose of 25,000 IU/m2 (dose cohort 0) for 6 doses MWF over a period of 2 weeks to 9 patients (as described below and in the following schema).
- Trial name
- NCT02283190
- Testing
- Erwinase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ashkan Emadi
Metastatic Breast Cancer
Study of ESR1 Mutations in Metastatic Breast Cancer
The purpose of the study is to determine the frequency ESR1 mutations by Digital PCR in patient with metastatic breast cancer.
- Trial name
- FMER (NCT02473120)
- Testing
- Determination of ESR1 mutations
- Where
- France
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centre Henri Becquerel
Advanced Solid Tumors
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
- Trial name
- NCT06096974
- Testing
- YL-17231
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Transfusion-dependent Beta-Thalassemia
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
The goal of this Non-Randomized Clinical Trial is to determine the effects of thalidomide on red blood cells in transfusion dependent beta thalassemia patients.
- Trial name
- NCT06146478
- Testing
- Thalidomide
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Blood Care Clinic
Adjuvant Drug Therapy
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
The goal of this clinical trial is to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT) sequential capecitabine versus single-agent capecitabine as adjuvant intensified therapy in patients with high-risk…
- Trial name
- STARTER (NCT07628504)
- Testing
- Sacituzumab Tirumotecan (sac-TMT), Capecitabine
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Fudan University
Prostate Cancer
Prevalence of the c.853delT Mutation of the HOXB13 Gene in Prostate Cancer in Martinique
In Martinique, prostate cancer incidence rates are nowadays among the highest worldwide with a high incidence of early-onset and familial forms.
- Trial name
- HOXB13_Mart (NCT05231915)
- Testing
- HOXB13 c.853delT mutation
- Where
- Martinique
- Volunteers
- 465 people
- Sponsor
- University Hospital Center of Martinique
Lipid Disorder
Genetic Origin of Lipid Disorders
Several lipid disorders are without known genetic origin. The scope of this project is to sequence genes superior involved in lipid and carbohydrate metabolism in patients with severe lipid disorders.
- Trial name
- NCT00277121
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Oslo
Amyotrophic Lateral Sclerosis
Frequency of SOD1 and C9orf72 Gene Mutations in French ALS
The purpose of the study is to determine the frequency of mutations in the C9orf72 and SOD1 genes in the incident population of ALS patients followed in the FILSLAN centres
- Trial name
- GENIALS (NCT04819555)
- Testing
- Blood
- Where
- 20 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Tours
Biliary Tract Cancer
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
This is a multicenter, non-randomized, umbrella, open-label phase II clinical study, aiming to observe and evaluate, as well as explore the efficacy and safety of precision targeted therapy based on NGS technology for…
- Trial name
- NCT07282262
- Testing
- Ivosidenib, Lenvatinib, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Alagille Syndrome
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome
The goal of the project is to identify and clone the gene(s) responsible for the Alagille Syndrome (AGS) by a positional cloning approach.
- Trial name
- NCT00001642
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.